Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 45Lymphoma, Mantle-Cell 22Waldenstrom Macroglobulinemia 12Lymphoma, Non-Hodgkin 10Lymphoma, Large B-Cell, Diffuse 10Lymphoma, Follicular 10Lymphoma, B-Cell 10Leukemia 10Recurrence 7Lymphoma, B-Cell, Marginal Zone 6Lymphoma 6Neoplasms 4Hodgkin Disease 4Leukemia, Prolymphocytic 3Leukemia, Lymphoid 3Leukemia, B-Cell 3Chromosome 17 deletion 3Burkitt Lymphoma 3Bronchiolitis Obliterans Syndrome 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Multiple Myeloma 2Leukemia, Myeloid, Acute 2Leukemia, Hairy Cell 2Hematologic Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Smoldering Multiple Myeloma 1Prostatic Neoplasms 1Neuroendocrine Tumors 1Neoplasms, Plasma Cell 1Neoplasm, Residual 1

Interventions

midostaurin 3avapritinib 2sarilumab 1obatoclax 1ibrutinib 1denileukin diftitox 1Imatinib Mesylate 1Everolimus 1Dasatinib 1Brentuximab Vedotin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Mastocytosis, Systemic × ibrutinib × Clear all
NCT02415608 2018-09-20

Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis

Stanford University

Phase 2 Terminated
4 enrolled 14 charts
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Mast-Cell, Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡